VRCDF (Verici Dx) Long-Term Debt : $0.00 Mil (As of Dec. 2024)

View and export this data going back to 2021. Start your Free Trial

What is Verici Dx Long-Term Debt?

Verici Dx's Long-Term Debt for the quarter that ended in Dec. 2024 was $0.00 Mil.

Verici Dx Long-Term Debt Historical Data

The historical data trend for Verici Dx's Long-Term Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Verici Dx Long-Term Debt Chart

Verici Dx Annual Data

Trend

Dec20

Dec21

Dec22

Dec23

Dec24

Long-Term Debt

Verici Dx Semi-Annual Data
	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23	Jun24	Dec24
Long-Term Debt	Get a 7-Day Free Trial				-	-	-	-	-

Verici Dx (OTCPK:VRCDF) Long-Term Debt Explanation

Long-Term Debt is the sum of the carrying values as of the balance sheet date of all long-term debt, which is debt initially having maturities due after one year or beyond the operating cycle, if longer, but excluding the portions thereof scheduled to be repaid within one year or the normal operating cycle, if longer. Long-Term Debt includes notes payable, bonds payable, mortgage loans, convertible debt, subordinated debt and other types of long term debt.

Verici Dx Long-Term Debt Related Terms

Thank you for viewing the detailed overview of Verici Dx's Long-Term Debt provided by GuruFocus.com. Please click on the following links to see related term pages.

Verici Dx Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Verici Dx PLC (OTCPK:VRCDF) » Definitions » Long-Term Debt

Comparable Companies

Traded in Other Exchanges

VRCI:UK 63V:Germany

Address

19 Stanwell Road, Avon House, Penarth, Cardiff, GBR, CF64 2EZ

Website

https://www.vericidx.com

Verici Dx PLC is an immuno-diagnostics development company. The company is focused on developing diagnostics technologies that will help understand the outcomes of an organ transplant surgery. There are two products for clinical validation and commercialization: Clarava, which is a pre-transplant prognosis for the risk of early acute rejection; and Tuteva, a post-transplant diagnostic focused upon acute cellular rejection including sub-clinical rejection not being diagnosed through the current standard of care of rising serum creatine levels. The business of the Group comprises a single activity, which of the development of prognostic and diagnostic tests for kidney transplant patients.

Verici Dx Headlines

No Headlines